Journal
ANTIBIOTICS-BASEL
Volume 12, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/antibiotics12061078
Keywords
delafloxacin; Pseudomonas aeruginosa; multidrug-resistance; carbapenem-resistance; carbapenem-resistant Pseudomonas aeruginosa; cystic fibrosis; fluoroquinolones
Categories
Ask authors/readers for more resources
Delafloxacin (DLX) is a newly approved fluoroquinolone that shows broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). DLX exhibits excellent penetration in the CF lung and has enhanced activity in low pH environments. In this study, DLX was compared to ciprofloxacin (CPX) and levofloxacin (LVX) against Psa strains isolated from CF sputum. DLX showed significant improvements in killing bacteria in a CF sputum time-kill model at physiologically relevant drug concentrations, making it a potential option for treating MDR-Psa pulmonary infections in CF patients.
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (p = 0.033) and Cmin (p = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (p = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available